{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T21:57:51Z","timestamp":1742939871895,"version":"3.40.3"},"publisher-location":"Cham","reference-count":85,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783031300394"},{"type":"electronic","value":"9783031300400"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-3-031-30040-0_1","type":"book-chapter","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T17:02:06Z","timestamp":1685552526000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Art of Stem Cell-Based Therapy"],"prefix":"10.1007","author":[{"given":"Jorge S.","family":"Burns","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,1]]},"reference":[{"key":"1_CR1","doi-asserted-by":"publisher","first-page":"789695","DOI":"10.3389\/fmed.2022.789695","volume":"9","author":"D Aboalola","year":"2022","unstructured":"Aboalola D, Badraiq H, Alsiary R, Zakri S, Aboulola N, Haneef L, Malibari D, Baadhaim M, Alsayegh K (2022) An infodemic of misinformation on stem cell therapy among the population of Saudi Arabia: a cross-sectional study. Front Med 9:789695","journal-title":"Front Med"},{"key":"1_CR2","doi-asserted-by":"publisher","first-page":"138996","DOI":"10.1016\/j.scitotenv.2020.138996","volume":"730","author":"T Acter","year":"2020","unstructured":"Acter T, Uddin N, Das J, Akhter A, Choudhury TR, Kim S (2020) Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: a global health emergency. Sci Total Environ 730:138996","journal-title":"Sci Total Environ"},{"key":"1_CR3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1177\/1073110516667937","volume":"44","author":"AJ Anderson","year":"2016","unstructured":"Anderson AJ, Cummings BJ (2016) Achieving informed consent for cellular therapies: a preclinical translational research perspective on regulations versus a dose of reality. J Law Med Ethics 44:394\u2013401","journal-title":"J Law Med Ethics"},{"key":"1_CR4","doi-asserted-by":"publisher","first-page":"90636","DOI":"10.18632\/oncotarget.21891","volume":"8","author":"Z Ansari","year":"2017","unstructured":"Ansari Z, Kuriyan A, Albini T (2017) Unproven stem cell therapy for macular degeneration. Oncotarget 8:90636","journal-title":"Oncotarget"},{"key":"1_CR5","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.stem.2021.05.009","volume":"28","author":"E Anthony","year":"2021","unstructured":"Anthony E, Lovell-Badge R, Morrison SJ (2021) New guidelines for stem cell and embryo research from the ISSCR. Cell Stem Cell 28:991\u2013992","journal-title":"Cell Stem Cell"},{"key":"1_CR6","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1016\/j.stemcr.2021.05.021","volume":"16","author":"LS Assen","year":"2021","unstructured":"Assen LS, Jongsma KR, Isasi R, Tryfonidou MA, Bredenoord AL (2021) Recognizing the ethical implications of stem cell research: a call for broadening the scope. Stem Cell Reports 16:1656\u20131661","journal-title":"Stem Cell Reports"},{"key":"1_CR7","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/sctm.17-0282","volume":"7","author":"G Bauer","year":"2018","unstructured":"Bauer G, Elsallab M, Abou-El-Enein M (2018) Concise review: a comprehensive analysis of reported adverse events in patients receiving unproven stem cell-based interventions. Stem Cells Transl Med 7:676\u2013685","journal-title":"Stem Cells Transl Med"},{"key":"1_CR8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/d41586-021-01618-3","volume":"594","author":"F Baylis","year":"2021","unstructured":"Baylis F (2021) ISSCR guidelines fudge heritable human-genome editing. Nature 594:333","journal-title":"Nature"},{"key":"1_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jcyt.2021.09.009","volume":"24","author":"A Bersenev","year":"2022","unstructured":"Bersenev A, Gustafson MP, Hanley PJ (2022) ISCT survey on hospital practices to support externally manufactured investigational cell-gene therapy products. Cytotherapy 24:27\u201331","journal-title":"Cytotherapy"},{"key":"1_CR10","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.3389\/fimmu.2019.01080","volume":"10","author":"LK Boland","year":"2019","unstructured":"Boland LK, Burand AJ, Boyt DT, Dobroski H, Di L, Liszewski JN, Schrodt MV, Frazer MK, Santillan DA, Ankrum JA (2019) Nature vs. nurture: defining the effects of mesenchymal stromal cell isolation and culture conditions on resiliency to palmitate challenge. Front Immunol 10:1080","journal-title":"Front Immunol"},{"key":"1_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jcyt.2012.10.008","volume":"15","author":"CA Bravery","year":"2013","unstructured":"Bravery CA, Carmen J, Fong T, Oprea W, Hoogendoorn KH, Woda J, Burger SR, Rowley JA, Bonyhadi ML, Van\u2019t Hof W (2013) Potency assay development for cellular therapy products: an ISCT review of the requirements and experiences in the industry. Cytotherapy 15:9\u201319.e9","journal-title":"Cytotherapy"},{"key":"1_CR12","doi-asserted-by":"publisher","first-page":"708950","DOI":"10.3389\/fimmu.2021.708950","volume":"12","author":"R Chinnadurai","year":"2021","unstructured":"Chinnadurai R, Bates PD, Kunugi KA, Nickel KP, DeWerd LA, Capitini CM, Galipeau J, Kimple RJ (2021) Dichotomic potency of IFN\u03b3 licensed allogeneic mesenchymal stromal cells in animal models of acute radiation syndrome and graft versus host disease. Front Immunol 12:708950","journal-title":"Front Immunol"},{"key":"1_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40883-021-00202-5","volume":"8","author":"A Chouw","year":"2022","unstructured":"Chouw A, Milanda T, Sartika CR, Kirana MN, Halim D, Faried A (2022) Potency of mesenchymal stem cell and its secretome in treating COVID-19. Regen Eng Transl Med 8:43\u201354","journal-title":"Regen Eng Transl Med"},{"key":"1_CR14","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1126\/science.abq7232","volume":"376","author":"J Cohen","year":"2022","unstructured":"Cohen J (2022) First self-copying mRNA vaccine proves itself in pandemic trial. Science 376:446","journal-title":"Science"},{"key":"1_CR15","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.jcyt.2022.03.007","volume":"24","author":"N Cuende","year":"2022","unstructured":"Cuende N, Ciccocioppo R, Forte M, Galipeau J, Ikonomou L, Levine BL, Srivastava A, Zettler PJ (2022) Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products. Cytotherapy 24:686\u2013690","journal-title":"Cytotherapy"},{"key":"1_CR16","doi-asserted-by":"publisher","first-page":"705019","DOI":"10.3389\/fgene.2021.705019","volume":"12","author":"L De Rosa","year":"2021","unstructured":"De Rosa L, Enzo E, Zardi G, Bodemer C, Magnoni C, Schneider H, De Luca M (2021) Hologene 5: a phase II\/III clinical trial of combined cell and gene therapy of junctional epidermolysis bullosa. Front Genet 12:705019","journal-title":"Front Genet"},{"key":"1_CR17","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jcyt.2021.12.009","volume":"24","author":"SA DeVeaux","year":"2022","unstructured":"DeVeaux SA, Ogle ME, Vyshnya S, Chiappa NF, Leitmann B, Rudy R, Day A, Mortensen LJ, Kurtzberg J, Roy K, Botchwey EA (2022) Characterizing human mesenchymal stromal cells\u2019 immune-modulatory potency using targeted lipidomic profiling of sphingolipids. Cytotherapy 24:608\u2013618","journal-title":"Cytotherapy"},{"key":"1_CR18","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1016\/j.vaccine.2007.02.076","volume":"25","author":"G Dinc","year":"2007","unstructured":"Dinc G, Ulman YI (2007) The introduction of variolation \u2018A La Turca\u2019 to the West by Lady Mary Montagu and Turkey\u2019s contribution to this. Vaccine 25:4261\u20134265","journal-title":"Vaccine"},{"key":"1_CR19","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/d41586-021-02483-w","volume":"597","author":"E Dolgin","year":"2021","unstructured":"Dolgin E (2021) The tangled history of mRNA vaccines. Nature 597:318\u2013324","journal-title":"Nature"},{"key":"1_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:315\u2013317","journal-title":"Cytotherapy"},{"key":"1_CR21","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/j.stemcr.2021.07.003","volume":"16","author":"R Fears","year":"2021","unstructured":"Fears R, Akutsu H, Alentajan-Aleta LT, Caicedo A, Campos de Carvalho AC, \u010coli\u0107 M, Cornish J, Cossu G, Debr\u00e9 P, Dierckxsens G, El-Badri N, Griffin G, Chingo-Ho Hsieh P, Inamdar MS, Kumar P, Abraham CM, Maciulaitis R, Al Mahtab M, O\u2019Brien FJ, Pepper MS, Meulen VT (2021) Inclusivity and diversity: integrating international perspectives on stem cell challenges and potential. Stem Cell Reports 16:1847\u20131852","journal-title":"Stem Cell Reports"},{"key":"1_CR22","doi-asserted-by":"publisher","first-page":"918565","DOI":"10.3389\/fimmu.2022.918565","volume":"13","author":"M Fern\u00e1ndez-Santos","year":"2022","unstructured":"Fern\u00e1ndez-Santos M, Garc\u00eda-Arranz M, Andreu E, Garc\u00eda-Hern\u00e1ndez A, L\u00f3pez-Parra M, Villar\u00f3n E, Sep\u00falveda P, Fern\u00e1ndez-Avil\u00e9s F, Garc\u00eda-Olmo D, Prosper F, S\u00e1nchez-Guijo F, Moraleda JM, Zapata A (2022) Optimization of mesenchymal stromal cell (MSC) manufacturing processes for a better therapeutic outcome. Front Immunol 13:918565","journal-title":"Front Immunol"},{"key":"1_CR23","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jcyt.2020.11.007","volume":"23","author":"J Galipeau","year":"2021","unstructured":"Galipeau J, Krampera M, Leblanc K, Nolta JA, Phinney DG, Shi Y, Tarte K, Viswanathan S, Martin I (2021) Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predisposition. Cytotherapy 23:368\u2013372","journal-title":"Cytotherapy"},{"key":"1_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10616-021-00474-3","volume":"73","author":"E Garc\u00eda-Mu\u00f1oz","year":"2021","unstructured":"Garc\u00eda-Mu\u00f1oz E, Vives J (2021) Towards the standardization of methods of tissue processing for the isolation of mesenchymal stromal cells for clinical use. Cytotechnology 73:1\u201310","journal-title":"Cytotechnology"},{"key":"1_CR25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s13770-021-00417-1","volume":"19","author":"RA Gonzalez-Vilchis","year":"2022","unstructured":"Gonzalez-Vilchis RA, Piedra-Ramirez A, Pati\u00f1o-Morales CC, Sanchez-Gomez C, Beltran-Vargas NE (2022) Sources, characteristics, and therapeutic applications of mesenchymal cells in tissue engineering. Tissue Eng Regen Med 19:325\u2013361","journal-title":"Tissue Eng Regen Med"},{"key":"1_CR26","first-page":"S29","volume":"28","author":"ZC Han","year":"2017","unstructured":"Han ZC, Du WJ, Han ZB, Liang L (2017) New insights into the heterogeneity and functional diversity of human mesenchymal stem cells. Biomed Mater Eng 28:S29\u2013S45","journal-title":"Biomed Mater Eng"},{"key":"1_CR27","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nature24487","volume":"551","author":"T Hirsch","year":"2017","unstructured":"Hirsch T, Rothoeft T, Teig N, Bauer JW, Pellegrini G, De Rosa L, Scaglione D, Reichelt J, Klausegger A, Kneisz D, Romano O, Secone Seconetti A, Contin R, Enzo E, Jurman I, Carulli S, Jacobsen F, Luecke T, Lehnhardt M, Fischer M, Kueckelhaus M, Quaglino D, Morgante M, Bicciato S, Bondanza S, De Luca M (2017) Regeneration of the entire human epidermis using transgenic stem cells. Nature 551:327\u2013332","journal-title":"Nature"},{"key":"1_CR28","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jcyt.2020.11.008","volume":"23","author":"C Iglesias-Lopez","year":"2021","unstructured":"Iglesias-Lopez C, Obach M, Vallano A, Agust\u00ed A (2021) Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States. Cytotherapy 23:261\u2013274","journal-title":"Cytotherapy"},{"key":"1_CR29","doi-asserted-by":"publisher","first-page":"648472","DOI":"10.3389\/fcell.2021.648472","volume":"9","author":"P Jayaraman","year":"2021","unstructured":"Jayaraman P, Lim R, Ng J, Vemuri MC (2021) Acceleration of translational mesenchymal stromal cell therapy through consistent quality GMP manufacturing. Front Cell Dev Biol 9:648472","journal-title":"Front Cell Dev Biol"},{"key":"1_CR30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/d41586-021-01697-2","volume":"594","author":"J Johnston","year":"2021","unstructured":"Johnston J, Baylis F, Greely HT (2021) ISSCR: grave omission of age limit for embryo research. Nature 594:495","journal-title":"Nature"},{"key":"1_CR31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s13287-022-02920-1","volume":"13","author":"N Kaffash Farkhad","year":"2022","unstructured":"Kaffash Farkhad N, Sedaghat A, Reihani H, Adhami Moghadam A, Bagheri Moghadam A, Khadem Ghaebi N, Khodadoust MA, Ganjali R, Tafreshian AR, Tavakol-Afshari J (2022) Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial. Stem Cell Res Ther 13:283","journal-title":"Stem Cell Res Ther"},{"key":"1_CR32","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2217\/pme-2021-0111","volume":"19","author":"P Kidpun","year":"2022","unstructured":"Kidpun P, Ruanglertboon W, Chalongsuk R (2022) State-of-the-art knowledge on the regulation of advanced therapy medicinal products. Per Med 19:251","journal-title":"Per Med"},{"key":"1_CR33","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1093\/stcltm\/szac038","volume":"11","author":"AM Kirkham","year":"2022","unstructured":"Kirkham AM, Bailey AJM, Monaghan M, Shorr R, Lalu MM, Fergusson DA, Allan DS (2022) Updated living systematic review and meta-analysis of controlled trials of mesenchymal stromal cells to treat COVID-19: a framework for accelerated synthesis of trial evidence for rapid approval-FASTER approval. Stem Cells Transl Med 11:675\u2013687","journal-title":"Stem Cells Transl Med"},{"key":"1_CR34","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.jcyt.2021.12.001","volume":"24","author":"AM Kirkham","year":"2022","unstructured":"Kirkham AM, Monaghan M, Bailey AJM, Shorr R, Lalu MM, Fergusson DA, Allan DS (2022) Mesenchymal stem\/stromal cell-based therapies for COVID-19: first iteration of a living systematic review and meta-analysis: MSCs and COVID-19. Cytotherapy 24:639\u2013649","journal-title":"Cytotherapy"},{"key":"1_CR35","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1016\/S2666-5247(21)00266-4","volume":"3","author":"I Knezevic","year":"2021","unstructured":"Knezevic I, Mattiuzzo G, Page M, Minor P, Griffiths E, Nuebling M, Moorthy V (2021) WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community. Lancet Microbe 3:e235","journal-title":"Lancet Microbe"},{"key":"1_CR36","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1089\/ars.2017.7159","volume":"29","author":"A Langrzyk","year":"2018","unstructured":"Langrzyk A, Nowak WN, St\u0119pniewski J, Ja\u017awa A, Florczyk-Soluch U, J\u00f3zkowicz A, Dulak J (2018) Critical view on mesenchymal stromal cells in regenerative medicine. Antioxid Redox Signal 29:169\u2013190","journal-title":"Antioxid Redox Signal"},{"key":"1_CR37","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s40883-020-00147-1","volume":"6","author":"CT Laurencin","year":"2020","unstructured":"Laurencin CT, McClinton A (2020) Regenerative cell-based therapies: cutting edge, bleeding edge, and off the edge. Regen Eng Transl Med 6:78\u201389","journal-title":"Regen Eng Transl Med"},{"key":"1_CR38","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3389\/fcell.2020.00316","volume":"8","author":"A Lavrentieva","year":"2020","unstructured":"Lavrentieva A, Hoffmann A, Lee-Thedieck C (2020) Limited potential or unfavorable manipulations? Strategies toward efficient mesenchymal stem\/stromal cell applications. Front Cell Dev Biol 8:316","journal-title":"Front Cell Dev Biol"},{"key":"1_CR39","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2144\/btn-2019-0143","volume":"67","author":"F Leask","year":"2019","unstructured":"Leask F (2019) Spotting \u2018unproven\u2019 stem cell therapies in the wild. BioTechniques 67:253","journal-title":"BioTechniques"},{"key":"1_CR40","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.jcyt.2022.01.007","volume":"24","author":"BL Levine","year":"2022","unstructured":"Levine BL, Munsie M, Levine AD, Ikonomou L, International SFCGTCOTEOCAGT (2022) The peril of the promise of speculative cell banking: statement from the ISCT Committee on the Ethics of Cell and Gene Therapy. Cytotherapy 24:977\u2013978","journal-title":"Cytotherapy"},{"key":"1_CR41","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/voxs.12636","volume":"16","author":"F Lim","year":"2021","unstructured":"Lim F (2021) Proven and unproven cell therapies \u2013 what we have learned so far. ISBT Sci Ser 16:213\u2013218","journal-title":"ISBT Sci Ser"},{"key":"1_CR42","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1056\/NEJMoa2117128","volume":"386","author":"DY Lin","year":"2022","unstructured":"Lin DY, Gu Y, Wheeler B, Young H, Holloway S, Sunny SK, Moore Z, Zeng D (2022) Effectiveness of Covid-19 vaccines over a 9-month period in North Carolina. N Engl J Med 386:933\u2013941","journal-title":"N Engl J Med"},{"issue":"9","key":"1_CR43","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1093\/stcltm\/szac050","volume":"11","author":"AJ Lipat","year":"2022","unstructured":"Lipat AJ, Cottle C, Pirlot BM, Mitchell J, Pando B, Helmly B, Kosko J, Rajan D, Hematti P, Chinnadurai R (2022) Chemokine assay matrix defines the potency of human bone marrow mesenchymal stromal cells. Stem Cells Transl Med 11(9):971\u2013986","journal-title":"Stem Cells Transl Med"},{"key":"1_CR44","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/d41586-021-01387-z","volume":"593","author":"R Lovell-Badge","year":"2021","unstructured":"Lovell-Badge R (2021) Stem-cell guidelines: why it was time for an update. Nature 593:479\u2013479","journal-title":"Nature"},{"key":"1_CR45","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.2217\/imt-2021-0245","volume":"14","author":"R Manoharan","year":"2022","unstructured":"Manoharan R, Kore RA, Mehta JL (2022) Mesenchymal stem cell treatment for hyperactive immune response in patients with COVID-19. Immunotherapy 14:1055","journal-title":"Immunotherapy"},{"key":"1_CR46","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s13287-021-02265-1","volume":"12","author":"A Markov","year":"2021","unstructured":"Markov A, Thangavelu L, Aravindhan S, Zekiy AO, Jarahian M, Chartrand MS, Pathak Y, Marofi F, Shamlou S, Hassanzadeh A (2021) Mesenchymal stem\/stromal cells as a valuable source for the treatment of immune-mediated disorders. Stem Cell Res Ther 12:192","journal-title":"Stem Cell Res Ther"},{"key":"1_CR47","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jama.2019.22238","volume":"323","author":"Z Master","year":"2020","unstructured":"Master Z, Smith C, Tilburt JC (2020) Informed consent for stem cell\u2013based interventions. JAMA 323:893\u2013893","journal-title":"JAMA"},{"key":"1_CR48","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jcyt.2020.11.005","volume":"23","author":"J Moody","year":"2021","unstructured":"Moody J, Milligan WD, St Onge M, Goonewardene A, Rivers P (2021) Cell and gene therapy: a snapshot of investor perspectives. Cytotherapy 23:256\u2013260","journal-title":"Cytotherapy"},{"key":"1_CR49","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/0141076818783658","volume":"111","author":"A Morabia","year":"2018","unstructured":"Morabia A (2018) Edward Jenner\u2019s 1798 report of challenge experiments demonstrating the protective effects of cowpox against smallpox. J R Soc Med 111:255","journal-title":"J R Soc Med"},{"key":"1_CR50","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.3390\/ijms23052850","volume":"23","author":"M Mousaei Ghasroldasht","year":"2022","unstructured":"Mousaei Ghasroldasht M, Seok J, Park HS, Liakath Ali FB, Al-Hendy A (2022) Stem cell therapy: from idea to clinical practice. Int J Mol Sci 23:2850","journal-title":"Int J Mol Sci"},{"key":"1_CR51","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12967-020-02234-x","volume":"18","author":"DKW Ocansey","year":"2020","unstructured":"Ocansey DKW, Pei B, Yan Y, Qian H, Zhang X, Xu W, Mao F (2020) Improved therapeutics of modified mesenchymal stem cells: an update. J Transl Med 18:42","journal-title":"J Transl Med"},{"key":"1_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/cells9122559","volume":"9","author":"AM Ofiteru","year":"2020","unstructured":"Ofiteru AM, Becheru DF, Gharbia S, Balta C, Herman H, Mladin B, Ionita M, Hermenean A, Burns JS (2020) Qualifying osteogenic potency assay metrics for human multipotent stromal cells: TGF-\u03b22 a telling eligible biomarker. Cells 9:E2559","journal-title":"Cells"},{"key":"1_CR53","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2217\/rme-2015-0051","volume":"11","author":"G Pellegrini","year":"2016","unstructured":"Pellegrini G, Lambiase A, Macaluso C, Pocobelli A, Deng S, Cavallini G, Esteki R, Rama P (2016) From discovery to approval of an advanced therapy medicinal product-containing stem cells, in the EU. Regen Med 11:407","journal-title":"Regen Med"},{"key":"1_CR54","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1056\/NEJMoa2106599","volume":"385","author":"T Pilishvili","year":"2021","unstructured":"Pilishvili T, Gierke R, Fleming-Dutra KE et al (2021) Effectiveness of mRNA Covid-19 vaccine among U.S. health care personnel. N Engl J Med 385:e90","journal-title":"N Engl J Med"},{"key":"1_CR55","first-page":"5","volume":"12","author":"V Pimpaneau","year":"2015","unstructured":"Pimpaneau V, Gianelli F, Trouvin JH, Poiseau AD (2015) The challenges of potency assay development for cell-based medicinal products in Europe. Regul Rapp 12:5\u201310","journal-title":"Regul Rapp"},{"key":"1_CR56","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000524392","volume":"49","author":"C Priesner","year":"2022","unstructured":"Priesner C, Hildebrandt M (2022) Advanced therapy medicinal products and the changing role of academia. Transfus Med Hemother 49:158","journal-title":"Transfus Med Hemother"},{"key":"1_CR57","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1056\/NEJMoa0905955","volume":"363","author":"P Rama","year":"2010","unstructured":"Rama P, Matuska S, Paganoni G, Spinelli A, De Luca M, Pellegrini G (2010) Limbal stem-cell therapy and long-term corneal regeneration. N Engl J Med 363:147\u2013155","journal-title":"N Engl J Med"},{"key":"1_CR58","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/stcltm\/szab009","volume":"11","author":"L Renesme","year":"2022","unstructured":"Renesme L, Pierro M, Cobey KD, Mital R, Nangle K, Shorr R, Lalu MM, Th\u00e9baud B (2022) Definition and characteristics of mesenchymal stromal cells in preclinical and clinical studies: a scoping review. Stem Cells Transl Med 11:44\u201354","journal-title":"Stem Cells Transl Med"},{"key":"1_CR59","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/08998280.2005.11928028","volume":"18","author":"S Riedel","year":"2005","unstructured":"Riedel S (2005) Edward Jenner and the history of smallpox and vaccination. Bayl Univ Med Cent Proc 18:21\u201325","journal-title":"Bayl Univ Med Cent Proc"},{"key":"1_CR60","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1159\/000129013","volume":"35","author":"MT Rojewski","year":"2008","unstructured":"Rojewski MT, Weber BM, Schrezenmeier H (2008) Phenotypic characterization of mesenchymal stem cells from various tissues. Transfus Med Hemother 35:168\u2013184","journal-title":"Transfus Med Hemother"},{"key":"1_CR61","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1177\/0363546521993788","volume":"49","author":"S Ruoss","year":"2021","unstructured":"Ruoss S, Walker JT, Nasamran CA, Fisch KM, Paez CJ, Parekh JN, Ball ST, Chen JL, Ahmed SS, Ward SR (2021) Strategies to identify mesenchymal stromal cells in minimally manipulated human bone marrow aspirate concentrate lack consensus. Am J Sports Med 49:1313\u20131322","journal-title":"Am J Sports Med"},{"key":"1_CR62","doi-asserted-by":"publisher","first-page":"10554","DOI":"10.1111\/jcmm.16986","volume":"25","author":"B Sadeghi","year":"2021","unstructured":"Sadeghi B, Roshandel E, Pirsalehi A, Kazemi S, Sankanian G, Majidi M, Salimi M, Aghdami N, Sadrosadat H, Samadi Kochaksaraei S, Alaeddini F, Ringden O, Hajifathali A (2021) Conquering the cytokine storm in COVID-19-induced ARDS using placenta-derived decidua stromal cells. J Cell Mol Med 25:10554\u201310564","journal-title":"J Cell Mol Med"},{"key":"1_CR63","volume":"13","author":"A Saleh","year":"2021","unstructured":"Saleh A, Qamar S, Tekin A, Singh R, Kashyap R (2021) Vaccine development throughout history. Cureus 13:e16635","journal-title":"Cureus"},{"key":"1_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-022-00470-4","volume":"7","author":"G Sanyal","year":"2022","unstructured":"Sanyal G (2022) Development of functionally relevant potency assays for monovalent and multivalent vaccines delivered by evolving technologies. npj Vaccines 7:1\u201310","journal-title":"npj Vaccines"},{"key":"1_CR65","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41541-021-00317-4","volume":"6","author":"G Sanyal","year":"2021","unstructured":"Sanyal G, S\u00e4rnef\u00e4lt A, Kumar A (2021) Considerations for bioanalytical characterization and batch release of COVID-19 vaccines. npj Vaccines 6:53","journal-title":"npj Vaccines"},{"key":"1_CR66","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrd3052","volume":"9","author":"CK Schneider","year":"2010","unstructured":"Schneider CK, Celis P, (CAT) TCFAT (2010) Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov 9:195\u2013201","journal-title":"Nat Rev Drug Discov"},{"key":"1_CR67","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202101995","volume":"11","author":"RS Schneider","year":"2022","unstructured":"Schneider RS, Vela AC, Williams EK, Martin KE, Lam WA, Garc\u00eda AJ (2022) High-throughput on-chip human mesenchymal stromal cell potency prediction. Adv Healthc Mater 11:e2101995","journal-title":"Adv Healthc Mater"},{"key":"1_CR68","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.3390\/cells10061301","volume":"10","author":"EY Shin","year":"2021","unstructured":"Shin EY, Yoon YJ, Lee JE, Shim SH, Park GH, Lee DR (2021) Identification of putative markers that predict the in vitro senescence of mesenchymal progenitor cells. Cells 10:1301","journal-title":"Cells"},{"key":"1_CR69","doi-asserted-by":"publisher","first-page":"eaag0426","DOI":"10.1126\/scitranslmed.aag0426","volume":"9","author":"D Sipp","year":"2017","unstructured":"Sipp D, Caulfield T, Kaye J, Barfoot J, Blackburn C, Chan S, Luca MD, Kent A, McCabe C, Munsie M, Sleeboom-Faulkner M, Sugarman J, Zimmeren EV, Zarzeczny A, Rasko J (2017) Marketing of unproven stem cell\u2013based interventions: a call to action. Sci Transl Med 9:eaag0426","journal-title":"Sci Transl Med"},{"key":"1_CR70","doi-asserted-by":"publisher","first-page":"874698","DOI":"10.3389\/fimmu.2022.874698","volume":"13","author":"MA Skibber","year":"2022","unstructured":"Skibber MA, Olson SD, Prabhakara KS, Gill BS, Cox CS (2022) Enhancing mesenchymal stromal cell potency: inflammatory licensing via mechanotransduction. Front Immunol 13:874698","journal-title":"Front Immunol"},{"key":"1_CR71","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3389\/fimmu.2011.00021","volume":"2","author":"KA Smith","year":"2011","unstructured":"Smith KA (2011) Edward jenner and the small pox vaccine. Front Immunol 2:21","journal-title":"Front Immunol"},{"key":"1_CR72","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jcyt.2021.11.009","volume":"24","author":"A Srinivasan","year":"2022","unstructured":"Srinivasan A, Sathiyanathan P, Yin L, Liu TM, Lam A, Ravikumar M, Smith RAA, Loh HP, Zhang Y, Ling L, Ng SK, Yang YS, Lezhava A, Hui J, Oh S, Cool SM (2022) Strategies to enhance immunomodulatory properties and reduce heterogeneity in mesenchymal stromal cells during ex vivo expansion. Cytotherapy 24:456\u2013472","journal-title":"Cytotherapy"},{"key":"1_CR73","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1001\/jama.2019.11290","volume":"322","author":"J Sugarman","year":"2019","unstructured":"Sugarman J, Barker R, Charo R (2019) A professional standard for informed consent for stem cell therapies. JAMA 322:1651","journal-title":"JAMA"},{"key":"1_CR74","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s41565-022-01071-x","volume":"17","author":"J Szebeni","year":"2022","unstructured":"Szebeni J, Storm G, Ljubimova JY, Castells M, Phillips EJ, Turjeman K, Barenholz Y, Crommelin DJA, Dobrovolskaia MA (2022) Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines. Nat Nanotechnol 17:337\u2013346","journal-title":"Nat Nanotechnol"},{"key":"1_CR75","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.stem.2020.05.003","volume":"26","author":"L Turner","year":"2020","unstructured":"Turner L (2020) Preying on public fears and anxieties in a pandemic: businesses selling unproven and unlicensed \u201cstem cell treatments\u201d for COVID-19. Cell Stem Cell 26:806","journal-title":"Cell Stem Cell"},{"key":"1_CR76","doi-asserted-by":"publisher","first-page":"806069","DOI":"10.3389\/fvets.2022.806069","volume":"9","author":"B Uberti","year":"2022","unstructured":"Uberti B, Plaza A, Henr\u00edquez C (2022) Pre-conditioning strategies for mesenchymal stromal\/stem cells in inflammatory conditions of livestock species. Front Vet Sci 9:806069","journal-title":"Front Vet Sci"},{"key":"1_CR77","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.jcyt.2019.08.002","volume":"21","author":"S Viswanathan","year":"2019","unstructured":"Viswanathan S, Shi Y, Galipeau J, Krampera M, Leblanc K, Martin I, Nolta J, Phinney DG, Sensebe L (2019) Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT\u00ae) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy 21:1019\u20131024","journal-title":"Cytotherapy"},{"key":"1_CR78","first-page":"393","volume":"7","author":"S Viswanathan","year":"2021","unstructured":"Viswanathan S, Ciccocioppo R, Galipeau J (2021) Consensus International Council for Commonality in Blood Banking Automation\u2013International Society for Cell & Gene Therapy statement on standard nomenclature abbreviations for the tissue of origin of mesenchymal stromal cells. Cytotherapy 7:393\u2013395","journal-title":"Cytotherapy"},{"key":"1_CR79","doi-asserted-by":"publisher","first-page":"eabn0071","DOI":"10.1126\/sciadv.abn0071","volume":"8","author":"X Wang","year":"2022","unstructured":"Wang X, Wang K, Yu M, Velluto D, Hong X, Wang B, Chiu A, Melero-Martin JM, Tomei AA, Ma M (2022) Engineered immunomodulatory accessory cells improve experimental allogeneic islet transplantation without immunosuppression. Sci Adv 8:eabn0071","journal-title":"Sci Adv"},{"key":"1_CR80","first-page":"31","volume":"3","author":"SM Watt","year":"2022","unstructured":"Watt SM (2022) The long and winding road: homeostatic and disordered haematopoietic microenvironmental niches: a narrative review. Biomater Transl 3:31","journal-title":"Biomater Transl"},{"key":"1_CR81","doi-asserted-by":"publisher","first-page":"867426","DOI":"10.3389\/fcell.2022.867426","volume":"10","author":"DM Wiese","year":"2022","unstructured":"Wiese DM, Wood CA, Braid LR (2022) From vial to vein: crucial gaps in mesenchymal stromal cell clinical trial reporting. Front Cell Dev Biol 10:867426","journal-title":"Front Cell Dev Biol"},{"key":"1_CR82","volume-title":"The global eradication of smallpox: final report of the Global Commission for the Certification of Smallpox Eradication, Geneva, December 1979","author":"World Health Organization","year":"1980","unstructured":"World Health Organization (1980) The global eradication of smallpox: final report of the Global Commission for the Certification of Smallpox Eradication, Geneva, December 1979. World Health Organization"},{"key":"1_CR83","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.reth.2022.05.002","volume":"21","author":"H Yui","year":"2022","unstructured":"Yui H, Muto K, Yashiro Y, Watanabe S, Kiya Y, Kamisato A, Inoue Y, Yamagata Z (2022) Comparison of the 2021 International Society for Stem Cell Research (ISSCR) guidelines for \u201claboratory-based human stem cell research, embryo research, and related research activities\u201d and the corresponding Japanese regulations. Regen Ther 21:46\u201351","journal-title":"Regen Ther"},{"key":"1_CR84","doi-asserted-by":"crossref","unstructured":"Chan LY, Dass SA, Tye GJ, Imran SAM, Wan Kamarul Zaman WS, Nordin F (2022) CAR-T Cells\/-NK Cells in Cancer Immunotherapy and the Potential of MSC to Enhance Its Efficacy: A Review. Biomedicines 10:804. https:\/\/doi.org\/10.3390\/biomedicines10040804","DOI":"10.3390\/biomedicines10040804"},{"key":"1_CR85","doi-asserted-by":"crossref","unstructured":"Hoang DM, Pham PT, Bach TQ, Ngo ATL, Nguyen QT, Phan TTK, Nguyen GH, Le PTT, Hoang VT, Forsyth NR, Heke M, Nguyen LT (2022) Stem cell-based therapy for human diseases. Signal Transduct Target Ther 7:272. https:\/\/doi.org\/10.1038\/s41392-022-01134-4","DOI":"10.1038\/s41392-022-01134-4"}],"container-title":["Advances in Experimental Medicine and Biology","Potency Assays for Advanced Stem Cell Therapy Medicinal Products"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-30040-0_1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T18:09:37Z","timestamp":1685556577000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-30040-0_1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9783031300394","9783031300400"],"references-count":85,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-30040-0_1","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"type":"print","value":"0065-2598"},{"type":"electronic","value":"2214-8019"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"1 June 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}